Caplin Point Laboratories Limited announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The company reported a consolidated total revenue of ₹576.5 crore for Q3 FY26, a 9.9% increase year-on-year (YoY) and a 2.1% increase quarter-on-quarter (QoQ). For the nine months ended December 31, 2025 (9MFY26), the total revenue stood at ₹1,674.2 crore, an increase of 11.2% YoY. Consolidated Profit After Tax (PAT) for Q3 FY26 was ₹165.9 crore, an 18.4% increase YoY, and for 9MFY26, PAT was ₹476.9 crore, a 20.5% increase YoY. EBITDA for Q3 FY26 was ₹223.4 crore, up 15.3% YoY, and for 9MFY26, it was ₹643.8 crore, up 17.1% YoY. The US market revenue for 9MFY26 was ₹335 crore, showing a 25% growth YoY. Free Cash Reserves were ₹1,381 crore, and Liquid Assets were ₹2,459 crore as of December 31, 2025. In Emerging Markets, the company is driving consistent growth with a revenue pipeline of $25 million from new tender orders in Central America. Mexico saw approvals for 25 products with a pipeline of over 100 products. Caplin Point is also acquiring industrial land in Mexico to set up a manufacturing and packaging facility. In the US and regulated markets, Caplin Steriles Limited (CSL) reported robust growth. CSL received EU GMP renewal and completed a Saudi FDA audit. The company has acquired multiple ANDAs to expand its sterile products segment in regulated markets, expecting launches in the US within 12-15 months. The company has allocated an enhanced Capex budget of approximately ₹1000 crore for investment projects, aimed at augmenting production capacities, widening product range, and achieving backward integration. These projects are financed through internal accruals.
